Britain and America have agreed to a major commercial pact that will keep zero import taxes on UK medicine products entering the US market.
The Terms of the Deal
As part of the deal, the UK has agreed to boost funding on pharmaceuticals through the NHS. This move secures that duties on these vital products will be held at nothing for a duration of 36 months.
This agreement is in response to earlier threats to significantly raise duties on patented drug imports, with potential rates mentioned up to double the cost.
"This deal with the United Kingdom reinforces the international landscape for cutting-edge drugs and establishes long-overdue fairness to U.S.–U.K. pharmaceutical trade," a release declared.
Economic Importance
Pharmaceuticals constitute one of the UK's most significant goods shipped to the US, which is easily the biggest destination for leading British pharmaceutical firms.
Export figures show that in the 12 months prior to the third quarter, the UK exported drugs valued at billions to the US. This value made up 17.4% of total UK exports in that timeframe.
"This deal secures employment, stimulates funding and paves the way for the UK to establish itself as a global hub for life sciences," the Business and Trade Secretary commented.
Specific NHS Changes
The agreement includes several specific commitments from the British government:
- Higher Cost Ceiling: The UK will increase the affordability limit at which it judges new therapies to be prohibitively costly by a quarter.
- Increased NHS Spending: There is a target to raise total NHS spending on treatments from 0.3% of the national economy to 0.6 percent over the coming ten years.
- Refund Ceiling: The percentage pharmaceutical firms must pay back to the NHS to stay within budget will be capped at 15%. Previously, refunds were more than 20%.
Recent Tensions
This agreement follows a protracted dispute between the sector and the ministers over spending levels and NHS adoption.
This friction were intensified by assertions that American patients were charged a premium for the equivalent treatments than patients in the UK and Europe.
In recent months, several large pharmaceutical investments in the UK have been halted or abandoned, while major expansions have been announced toward American operations.
The Science Minister acknowledged that the NHS had to spend more on treatments, noting that its expenditure on drugs had declined as a percentage of its overall budget over the last ten years.
